Optimi Health (OPTI) Registration filing summary

Company overview and business model

• Vertically integrated Canadian GMP pharmaceutical manufacturer specializing in MDMA and psilocybin for therapeutic and research use, with two 10,000 sq. ft. facilities in British Columbia.

• Holds Health Canada Drug Establishment Licence (DEL), Dealer's Licence (DL), and Precursor Licence, enabling legal manufacture, export, and supply of controlled substances to regulated markets.

• Currently supplies MDMA and psilocybin to Australia’s Authorised Prescribers Scheme and clinical trials in Canada and Israel; U.S. entry contingent on regulatory changes.

• Focused on scaling production, regulatory compliance, and expanding into new markets, including the U.S. and Israel.

• Winding down nutraceutical business to focus exclusively on pharmaceutical-grade manufacturing.

Financial performance and metrics

• Fiscal year ended September 30, 2025: revenue C$426,301 (US$306,097), net loss C$3,712,031 (US$2,665,349), accumulated deficit C$27,241,680 (US$20,001,233).

• Three months ended December 31, 2025: revenue C$232,700, net loss C$1,553,975 (US$1,133,296).

• Cash and cash equivalents as of December 31, 2025: C$491,750.

• Ongoing operating losses, negative gross margin, and reliance on external financing; debt forgiveness of C$1,417,615 in FY2025.

• Capitalization post-offering: pro forma shareholders’ equity US$15.9 million, immediate dilution of US$3.22 per share to new investors at US$6.00/share IPO price.

Use of proceeds and capital allocation

• Net proceeds of approximately US$13.7 million (US$15.8 million if over-allotment exercised) expected at US$6.00/share IPO price.

• 25.5% for scaling production/distribution in current markets, 16.0% for market entry to Israel and U.S., 58.5% for general working capital and operating expenses.

• Management has broad discretion over use of funds; additional capital likely needed for U.S. market entry beyond 12 months.